Praxis Precision Medicines (PRAX) Financials

$38.45 +1.42 (+3.83%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$38.41 -0.04 (-0.10%)

As of 05/29/2025 04:20 PM Eastern

Annual Income Statements for Praxis Precision Medicines

This table shows Praxis Precision Medicines' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-183	-123	-214
Consolidated Net Income / (Loss)	-183	-123	-214
Net Income / (Loss) Continuing Operations	-183	-123	-214
Total Pre-Tax Income	-183	-123	-214
Total Operating Income	-200	-126	-215
Total Gross Profit	8.55	2.45	0.00
Total Revenue	8.55	2.45	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	209	129	215
Selling, General & Admin Expense	56	42	60
Research & Development Expense	152	87	155
Total Other Income / (Expense), net	17	3.10	0.96
Other Income / (Expense), net	17	3.10	0.96
Basic Earnings per Share	($10.21)	($18.69)	($69.65)
Weighted Average Basic Shares Outstanding	17.91M	6.59M	3.07M
Diluted Earnings per Share	($10.21)	($18.69)	($69.65)
Weighted Average Diluted Shares Outstanding	17.91M	6.59M	3.07M
Weighted Average Basic & Diluted Shares Outstanding	20.16M	13.24M	52.39M

This table shows Praxis Precision Medicines' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-69	-59	-52	-33	-40	-27	-25	-34	-37	-41	-44
Consolidated Net Income / (Loss)	-69	-59	-52	-33	-40	-27	-25	-34	-37	-41	-44
Net Income / (Loss) Continuing Operations	-69	-59	-52	-33	-40	-27	-25	-34	-37	-41	-44
Total Pre-Tax Income	-69	-59	-52	-33	-40	-27	-25	-34	-37	-41	-44
Total Operating Income	-75	-64	-57	-37	-42	-28	-26	-35	-38	-41	-44
Total Gross Profit	0.00	7.46	0.30	0.36	0.43	0.52	0.47	0.78	0.68	-	0.00
Total Revenue	0.00	7.46	0.30	0.36	0.43	0.52	0.47	0.78	0.68	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	75	71	57	38	42	28	26	36	39	41	44
Selling, General & Admin Expense	14	15	15	11	15	9.93	8.72	10	13	13	14
Research & Development Expense	61	56	42	27	27	18	17	26	26	28	30
Total Other Income / (Expense), net	5.43	5.28	4.93	4.81	2.33	0.93	0.88	0.65	0.64	0.28	0.35
Other Income / (Expense), net	5.43	5.28	4.93	4.81	2.33	0.93	0.88	0.65	0.64	0.28	0.35
Basic Earnings per Share	($3.29)	($3.28)	($2.75)	($1.74)	($2.84)	($4.08)	($2.72)	($7.38)	($10.58)	($13.40)	($0.96)
Weighted Average Basic Shares Outstanding	21.06M	17.91M	18.88M	18.82M	13.90M	6.59M	9.04M	4.65M	3.54M	3.07M	45.77M
Diluted Earnings per Share	($3.29)	($3.28)	($2.75)	($1.74)	($2.84)	($4.08)	($2.72)	($7.38)	($10.58)	($13.40)	($0.96)
Weighted Average Diluted Shares Outstanding	21.06M	17.91M	18.88M	18.82M	13.90M	6.59M	9.04M	4.65M	3.54M	3.07M	45.77M
Weighted Average Basic & Diluted Shares Outstanding	20.37M	20.16M	18.64M	17.76M	17.11M	13.24M	128.55M	128.54M	62.10M	52.39M	47.12M

This table details how cash moves in and out of Praxis Precision Medicines' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	134	20	-78
Net Cash From Operating Activities	-132	-111	-185
Net Cash From Continuing Operating Activities	-132	-111	-185
Net Income / (Loss) Continuing Operations	-183	-123	-214
Consolidated Net Income / (Loss)	-183	-123	-214
Depreciation Expense	0.36	0.43	0.42
Amortization Expense	-5.01	0.05	1.00
Non-Cash Adjustments To Reconcile Net Income	45	26	29
Changes in Operating Assets and Liabilities, net	11	-14	-1.78
Net Cash From Investing Activities	-248	39	97
Net Cash From Continuing Investing Activities	-248	39	97
Purchase of Property, Plant & Equipment	0.00	-0.05	-0.44
Purchase of Investments	-372	0.00	-83
Sale and/or Maturity of Investments	123	39	180
Net Cash From Financing Activities	514	92	10
Net Cash From Continuing Financing Activities	514	92	10
Issuance of Common Equity	515	92	11
Other Financing Activities, net	-0.31	-0.14	-0.26

This table details how cash moves in and out of Praxis Precision Medicines' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-50	47	24	-6.84	71	-20	-23	43	19	-0.83	6.40
Net Cash From Operating Activities	-53	-56	-28	-27	-21	-24	-23	-31	-33	-29	-45
Net Cash From Continuing Operating Activities	-53	-56	-28	-27	-21	-23	-24	-31	-33	-29	-45
Net Income / (Loss) Continuing Operations	-69	-59	-52	-33	-40	-27	-25	-34	-37	-41	-44
Consolidated Net Income / (Loss)	-69	-59	-52	-33	-40	-27	-25	-34	-37	-41	-44
Depreciation Expense	0.05	0.05	0.09	0.11	0.11	0.11	0.11	0.11	0.11	0.11	0.10
Amortization Expense	-1.23	-1.39	-2.01	-1.53	-0.08	-	-	0.00	0.05	0.20	0.21
Non-Cash Adjustments To Reconcile Net Income	8.48	8.82	13	6.11	17	7.12	4.80	6.42	7.35	6.56	6.92
Changes in Operating Assets and Liabilities, net	8.74	-4.92	14	0.72	1.47	-3.78	-3.92	-3.23	-3.10	5.50	-8.21
Net Cash From Investing Activities	-51	-11	50	-196	-91	-0.05	-	5.00	34	23	48
Net Cash From Continuing Investing Activities	-51	-11	50	-196	-91	-	-0.05	5.00	34	23	48
Purchase of Property, Plant & Equipment	-0.06	-	-	-	-	-	-	-	-	-	-0.05
Purchase of Investments	-117	-69	-12	-199	-91	-	-	-	0.00	-	-
Sale and/or Maturity of Investments	66	59	62	3.00	0.00	-	-	5.00	34	23	48
Net Cash From Financing Activities	54	114	1.44	216	183	4.13	-	70	18	5.39	3.37
Net Cash From Continuing Financing Activities	54	114	1.44	216	183	4.13	-	70	18	5.39	3.37
Issuance of Common Equity	55	114	1.44	216	183	4.13	0.00	70	18	5.39	3.37
Other Financing Activities, net	-0.64	-0.16	-0.00	-0.01	-0.14	-0.01	-0.00	-0.00	-0.13	-0.01	-0.01

This table presents Praxis Precision Medicines' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	483	88	115
Total Current Assets	404	85	111
Cash & Equivalents	215	81	62
Short-Term Investments	177	0.00	39
Prepaid Expenses	12	3.58	10
Plant, Property, & Equipment, net	0.23	0.59	0.97
Total Noncurrent Assets	79	2.48	3.32
Long-Term Investments	77	0.00	-
Other Noncurrent Operating Assets	1.55	2.48	3.32
Total Liabilities & Shareholders' Equity	483	88	115
Total Liabilities	38	18	39
Total Current Liabilities	38	16	34
Accounts Payable	13	5.82	15
Accrued Expenses	24	7.42	16
Current Deferred Revenue	0.00	1.39	2.82
Other Current Liabilities	1.26	1.13	1.01
Total Noncurrent Liabilities	0.11	2.53	4.68
Noncurrent Deferred Revenue	0.00	1.16	2.18
Other Noncurrent Operating Liabilities	0.11	1.37	2.50
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	445	70	76
Total Preferred & Common Equity	445	70	76
Preferred Stock	0.00	0.00	0.00
Total Common Equity	445	70	76
Common Stock	1,282	724	607
Retained Earnings	-837	-654	-531
Accumulated Other Comprehensive Income / (Loss)	0.65	0.00	-0.17

This table presents Praxis Precision Medicines' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	479	416	441	250	107	133	98	137
Total Current Assets	334	360	357	212	103	130	94	132
Cash & Equivalents	166	169	145	152	101	124	81	62
Short-Term Investments	162	188	207	55	0.00	0.00	4.98	61
Prepaid Expenses	5.58	3.02	4.84	4.39	2.24	5.53	8.58	8.57
Plant, Property, & Equipment, net	0.25	0.28	0.37	0.48	0.70	0.76	0.87	1.08
Total Noncurrent Assets	145	56	84	38	2.70	2.91	3.12	3.51
Long-Term Investments	144	54	82	36	-	-	-	-
Other Noncurrent Operating Assets	0.88	1.79	2.03	2.26	2.70	2.91	3.12	3.51
Total Liabilities & Shareholders' Equity	479	416	441	250	107	133	98	137
Total Liabilities	40	34	22	21	20	28	34	32
Total Current Liabilities	40	33	21	19	17	24	30	29
Accounts Payable	23	15	8.20	9.40	7.17	8.01	17	10
Accrued Expenses	16	15	10	6.98	6.98	13	9.35	18
Other Current Liabilities	1.07	1.22	1.19	1.16	1.10	1.06	1.04	0.98
Total Noncurrent Liabilities	0.00	0.73	1.34	1.93	3.18	3.44	4.00	2.76
Other Noncurrent Operating Liabilities	0.00	0.44	0.76	1.07	1.66	1.95	2.23	2.76
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	439	383	419	230	87	106	64	105
Total Preferred & Common Equity	439	383	419	230	87	106	64	105
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	439	383	419	230	87	106	64	105
Common Stock	1,345	1,159	1,145	923	714	708	633	595
Retained Earnings	-906	-778	-726	-693	-627	-602	-568	-489
Accumulated Other Comprehensive Income / (Loss)	0.66	1.33	-0.07	0.00	0.00	0.00	-0.02	-0.54

This table displays calculated financial ratios and metrics derived from Praxis Precision Medicines' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	249.53%	0.00%	0.00%
EBITDA Growth	-52.67%	42.24%	-28.80%
EBIT Growth	-48.30%	42.40%	-27.91%
NOPAT Growth	-58.39%	41.22%	-28.48%
Net Income Growth	-48.30%	42.40%	-28.11%
EPS Growth	45.37%	73.17%	-28.11%
Operating Cash Flow Growth	-18.55%	39.94%	-48.56%
Free Cash Flow Firm Growth	-26.14%	33.06%	-49.44%
Invested Capital Growth	-107.02%	52.30%	2.85%
Revenue Q/Q Growth	432.90%	26.66%	0.00%
EBITDA Q/Q Growth	-21.56%	10.30%	7.70%
EBIT Q/Q Growth	-21.06%	10.39%	7.82%
NOPAT Q/Q Growth	-22.04%	9.75%	7.41%
Net Income Q/Q Growth	-21.06%	10.39%	7.52%
EPS Q/Q Growth	-27.63%	-22.80%	7.52%
Operating Cash Flow Q/Q Growth	-32.42%	4.26%	7.98%
Free Cash Flow Firm Q/Q Growth	-26.87%	1.03%	6.90%
Invested Capital Q/Q Growth	15.54%	18.83%	-31.25%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	0.00%
EBITDA Margin	-2,191.87%	-5,018.31%	0.00%
Operating Margin	-2,340.29%	-5,164.41%	0.00%
EBIT Margin	-2,137.48%	-5,037.88%	0.00%
Profit (Net Income) Margin	-2,137.48%	-5,037.88%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-70.98%	-169.13%	-130.94%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-64.03%	-121.41%	0.00%
Return on Assets (ROA)	-64.03%	-121.41%	0.00%
Return on Common Equity (ROCE)	-70.98%	-169.13%	-130.94%
Return on Equity Simple (ROE_SIMPLE)	-41.04%	-176.95%	-281.22%
Net Operating Profit after Tax (NOPAT)	-140	-88	-150
NOPAT Margin	-1,638.20%	-3,615.08%	0.00%
Net Nonoperating Expense Percent (NNEP)	-15.51%	-38.30%	-33.76%
Return On Investment Capital (ROIC_SIMPLE)	-31.45%	-126.97%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	658.31%	1,718.59%	0.00%
R&D to Revenue	1,781.98%	3,545.81%	0.00%
Operating Expenses to Revenue	2,440.29%	5,264.41%	0.00%
Earnings before Interest and Taxes (EBIT)	-183	-123	-214
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-187	-123	-213
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.22	2.74	1.47
Price to Tangible Book Value (P/TBV)	3.22	2.74	1.47
Price to Revenue (P/Rev)	167.70	78.03	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	112.81	44.81	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.07	-1.25	-1.15
Leverage Ratio	1.11	1.39	1.25
Compound Leverage Factor	1.11	1.39	1.25
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	20.11	-7.80	-10.07
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	10.77	5.39	3.23
Quick Ratio	10.45	5.16	2.93
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-128	-101	-151
Operating Cash Flow to CapEx	0.00%	-222,272.00%	-41,676.35%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.03	0.02	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	20.91	3.14	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-24	-12	-24
Invested Capital Turnover	-0.48	-0.14	0.00
Increase / (Decrease) in Invested Capital	-12	13	0.72
Enterprise Value (EV)	965	110	12
Market Capitalization	1,434	191	112
Book Value per Share	$23.90	$0.54	$1.62
Tangible Book Value per Share	$23.90	$0.54	$1.62
Total Capital	445	70	76
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-470	-81	-100
Capital Expenditures (CapEx)	0.00	0.05	0.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-26	-12	-24
Debt-free Net Working Capital (DFNWC)	367	69	76
Net Working Capital (NWC)	367	69	76
Net Nonoperating Expense (NNE)	43	35	64
Net Nonoperating Obligations (NNO)	-470	-81	-100
Total Depreciation and Amortization (D&A)	-4.65	0.48	1.42
Debt-free, Cash-free Net Working Capital to Revenue	-301.01%	-497.30%	0.00%
Debt-free Net Working Capital to Revenue	4,288.81%	2,825.13%	0.00%
Net Working Capital to Revenue	4,288.81%	2,825.13%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($10.21)	($18.69)	($69.60)
Adjusted Weighted Average Basic Shares Outstanding	17.91M	6.59M	3.07M
Adjusted Diluted Earnings per Share	($10.21)	($18.69)	($69.60)
Adjusted Weighted Average Diluted Shares Outstanding	17.91M	6.59M	3.07M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	20.16M	13.24M	3.49M
Normalized Net Operating Profit after Tax (NOPAT)	-140	-88	-150
Normalized NOPAT Margin	-1,638.20%	-3,615.08%	0.00%
Pre Tax Income Margin	-2,137.48%	-5,037.88%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.12%

This table displays calculated financial ratios and metrics derived from Praxis Precision Medicines' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-100.00%	1,349.13%	-35.47%	-54.29%	-36.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-78.31%	-124.24%	-119.48%	0.30%	-5.95%	34.51%	43.80%	42.85%	45.34%	29.45%	0.88%
EBIT Growth	-75.20%	-118.32%	-110.74%	4.77%	-5.60%	34.72%	43.95%	43.00%	45.49%	29.81%	1.69%
NOPAT Growth	-78.41%	-130.01%	-122.74%	-7.23%	-9.96%	32.92%	42.39%	42.11%	44.67%	29.33%	1.08%
Net Income Growth	-75.20%	-118.32%	-110.74%	4.77%	-5.60%	34.72%	43.95%	43.00%	45.49%	29.72%	1.70%
EPS Growth	-15.85%	19.61%	-1.10%	76.42%	73.16%	69.55%	43.95%	43.00%	45.49%	29.72%	4.00%
Operating Cash Flow Growth	-154.16%	-135.20%	-18.46%	12.61%	36.50%	17.17%	48.32%	45.44%	39.30%	35.78%	-87.46%
Free Cash Flow Firm Growth	10.69%	-0.33%	-15.82%	6.64%	-0.72%	-8.35%	28.39%	-52.85%	-67.32%	-18.40%	-65.11%
Invested Capital Growth	-141.14%	-107.02%	-98.95%	21.12%	36.28%	52.30%	22.87%	29.62%	32.20%	2.85%	-0.70%
Revenue Q/Q Growth	-100.00%	2,371.19%	-15.41%	-17.17%	-16.31%	10.04%	-40.08%	14.35%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-17.42%	-11.52%	-57.83%	13.72%	-47.66%	-9.15%	28.30%	8.31%	8.73%	6.33%	27.10%
EBIT Q/Q Growth	-18.09%	-13.04%	-58.86%	17.38%	-47.16%	-9.12%	28.21%	8.39%	9.03%	6.31%	26.99%
NOPAT Q/Q Growth	-16.84%	-12.53%	-51.61%	10.50%	-50.64%	-8.97%	27.01%	8.22%	8.11%	6.41%	26.66%
Net Income Q/Q Growth	-18.09%	-13.04%	-58.86%	17.38%	-47.16%	-9.12%	28.21%	8.39%	9.03%	6.31%	26.99%
EPS Q/Q Growth	-0.30%	-19.27%	-58.05%	38.73%	30.39%	-50.00%	28.21%	8.39%	9.03%	6.31%	27.27%
Operating Cash Flow Q/Q Growth	5.55%	-104.08%	-0.81%	-30.79%	12.59%	-2.78%	25.63%	4.97%	-14.02%	35.87%	21.48%
Free Cash Flow Firm Q/Q Growth	-2.43%	-26.23%	15.17%	18.57%	-15.06%	-45.71%	31.62%	12.15%	-23.78%	3.70%	-45.96%
Invested Capital Q/Q Growth	-36.26%	15.54%	-93.52%	-8.27%	-16.98%	18.83%	23.27%	12.55%	12.42%	-31.25%	29.99%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%
EBITDA Margin	0.00%	-804.26%	-17,822.19%	-9,552.10%	-9,170.53%	-5,197.48%	-5,239.96%	-4,379.51%	-5,461.79%	0.00%	0.00%
Operating Margin	0.00%	-856.97%	-18,819.54%	-10,500.84%	-9,718.33%	-5,399.22%	-5,452.14%	-4,476.31%	-5,577.01%	0.00%	0.00%
EBIT Margin	0.00%	-786.27%	-17,188.74%	-9,153.22%	-9,177.03%	-5,219.03%	-5,263.25%	-4,393.34%	-5,483.89%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	-786.27%	-17,188.74%	-9,153.22%	-9,177.03%	-5,219.03%	-5,263.25%	-4,393.34%	-5,483.89%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-63.56%	-70.98%	-64.34%	-47.16%	-85.25%	-169.13%	-143.36%	-128.33%	-143.07%	-130.94%	-115.41%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-23.55%	-105.50%	-56.43%	-115.50%	-125.78%	-83.48%	-40.98%	-22.17%	0.00%	0.00%
Return on Assets (ROA)	0.00%	-23.55%	-105.50%	-56.43%	-115.50%	-125.78%	-83.48%	-40.98%	-22.17%	0.00%	0.00%
Return on Common Equity (ROCE)	-63.56%	-70.98%	-64.34%	-47.16%	-85.25%	-169.13%	-143.36%	-128.33%	-143.07%	-130.94%	-115.41%
Return on Equity Simple (ROE_SIMPLE)	-48.40%	0.00%	-39.46%	-29.53%	-54.59%	0.00%	-158.57%	-148.53%	-283.50%	0.00%	-220.08%
Net Operating Profit after Tax (NOPAT)	-52	-45	-40	-26	-29	-19	-18	-24	-27	-29	-31
NOPAT Margin	0.00%	-599.88%	-13,173.68%	-7,350.59%	-6,802.83%	-3,779.46%	-3,816.50%	-3,133.42%	-3,903.91%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.75%	-5.05%	-4.73%	-2.31%	-6.22%	-8.16%	-6.02%	-6.79%	-7.00%	-6.46%	-5.91%
Return On Investment Capital (ROIC_SIMPLE)	-11.91%	-10.05%	-	-	-	-27.94%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	202.75%	5,051.66%	2,964.99%	3,557.54%	1,928.74%	1,864.10%	1,296.67%	1,942.90%	0.00%	0.00%
R&D to Revenue	0.00%	754.23%	13,867.88%	7,635.85%	6,260.79%	3,570.49%	3,688.03%	3,279.64%	3,734.11%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	956.97%	18,919.54%	10,600.84%	9,818.33%	5,499.22%	5,552.14%	4,576.31%	5,677.01%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-69	-59	-52	-33	-40	-27	-25	-34	-37	-41	-44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-70	-60	-54	-34	-40	-27	-25	-34	-37	-41	-44
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.74	3.22	2.67	1.69	3.52	2.74	2.53	0.68	0.66	1.47	0.98
Price to Tangible Book Value (P/TBV)	1.74	3.22	2.67	1.69	3.52	2.74	2.53	0.68	0.66	1.47	0.98
Price to Revenue (P/Rev)	94.01	167.70	636.60	399.54	368.02	78.03	113.77	48.78	62.06	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	35.90	112.81	380.42	154.57	257.18	44.81	61.45	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.07	-1.07	-1.09	-1.06	-1.12	-1.25	-1.17	-1.18	-1.21	-1.15	-1.09
Leverage Ratio	1.09	1.11	1.11	1.10	1.19	1.39	1.27	1.28	1.32	1.25	1.15
Compound Leverage Factor	1.09	1.11	1.11	1.10	1.19	1.39	1.27	1.28	1.32	1.25	1.15
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	9.22	20.96	16.17	17.70	19.92	-4.18	-1.39	-4.67	-7.80	-5.11	-3.20
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.44	10.77	10.96	17.30	11.27	5.39	6.15	5.31	3.16	3.23	4.57
Quick Ratio	8.30	10.45	10.86	17.06	11.04	5.16	6.02	5.09	2.87	2.93	4.27
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-33	-32	-26	-30	-37	-32	-22	-32	-37	-30	-31
Operating Cash Flow to CapEx	-82,828.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-99,820.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.03	0.01	0.01	0.01	0.02	0.02	0.01	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	22.47	20.91	3.29	3.14	3.27	3.14	2.17	1.55	0.68	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-33	-24	-29	-15	-14	-12	-14	-19	-21	-24	-19
Invested Capital Turnover	-0.35	-0.48	-0.07	-0.11	-0.13	-0.14	-0.12	-0.06	-0.03	0.00	0.00
Increase / (Decrease) in Invested Capital	-19	-12	-14	3.94	7.75	13	4.25	7.86	10	0.72	-0.13
Enterprise Value (EV)	292	965	611	274	565	110	119	-53	-43	12	-20
Market Capitalization	764	1,434	1,022	708	808	191	220	71	42	112	103
Book Value per Share	$21.78	$23.90	$21.55	$24.50	$17.35	$0.54	$0.67	$1.70	$1.23	$1.62	$2.31
Tangible Book Value per Share	$21.78	$23.90	$21.55	$24.50	$17.35	$0.54	$0.67	$1.70	$1.23	$1.62	$2.31
Total Capital	439	445	383	419	230	70	87	106	64	76	105
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-472	-470	-411	-434	-243	-81	-101	-124	-86	-100	-124
Capital Expenditures (CapEx)	0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-34	-26	-30	-16	-14	-12	-15	-19	-21	-24	-20
Debt-free Net Working Capital (DFNWC)	294	367	327	336	193	69	87	105	64	76	103
Net Working Capital (NWC)	294	367	327	336	193	69	87	105	64	76	103
Net Nonoperating Expense (NNE)	17	14	12	6.44	10	7.41	6.77	9.84	11	12	13
Net Nonoperating Obligations (NNO)	-472	-470	-411	-434	-243	-81	-101	-124	-86	-100	-124
Total Depreciation and Amortization (D&A)	-1.18	-1.34	-1.91	-1.42	0.03	0.11	0.11	0.11	0.15	0.30	0.31
Debt-free, Cash-free Net Working Capital to Revenue	-417.85%	-301.01%	-1,859.50%	-891.19%	-656.31%	-497.30%	-753.11%	-1,291.05%	-3,123.87%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	3,620.45%	4,288.81%	20,385.48%	18,977.75%	8,793.17%	2,825.13%	4,479.04%	7,199.39%	9,441.58%	0.00%	0.00%
Net Working Capital to Revenue	3,620.45%	4,288.81%	20,385.48%	18,977.75%	8,793.17%	2,825.13%	4,479.04%	7,199.39%	9,441.58%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.29)	($3.28)	($2.75)	($1.74)	($2.84)	($4.08)	($2.70)	($7.35)	($10.65)	($201.00)	($14.40)
Adjusted Weighted Average Basic Shares Outstanding	21.06M	17.91M	18.88M	18.82M	13.90M	6.59M	9.04M	4.65M	3.54M	204.87K	3.05M
Adjusted Diluted Earnings per Share	($3.29)	($3.28)	($2.75)	($1.74)	($2.84)	($4.08)	($2.70)	($7.35)	($10.65)	($201.00)	($14.40)
Adjusted Weighted Average Diluted Shares Outstanding	21.06M	17.91M	18.88M	18.82M	13.90M	6.59M	9.04M	4.65M	3.54M	204.87K	3.05M
Adjusted Basic & Diluted Earnings per Share	$0.00	($3.28)	$0.00	$0.00	$0.00	($4.08)	$0.00	$0.00	$0.00	($201.00)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	20.37M	20.16M	18.64M	17.76M	17.11M	13.24M	8.57M	8.57M	4.14M	3.49M	3.14M
Normalized Net Operating Profit after Tax (NOPAT)	-52	-45	-40	-26	-29	-19	-18	-24	-27	-29	-31
Normalized NOPAT Margin	0.00%	-599.88%	-13,173.68%	-7,350.59%	-6,802.83%	-3,779.46%	-3,816.50%	-3,133.42%	-3,903.91%	0.00%	0.00%
Pre Tax Income Margin	0.00%	-786.27%	-17,188.74%	-9,153.22%	-9,177.03%	-5,219.03%	-5,263.25%	-4,393.34%	-5,483.89%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.12%	-0.11%

Frequently Asked Questions About Praxis Precision Medicines' Financials

When does Praxis Precision Medicines's financial year end?

According to the most recent income statement we have on file, Praxis Precision Medicines' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Praxis Precision Medicines' net income changed over the last 2 years?

Praxis Precision Medicines' net income appears to be on a downward trend, with a most recent value of -$182.82 million in 2024, falling from -$214.03 million in 2022. The previous period was -$123.28 million in 2023. See where experts think Praxis Precision Medicines is headed by visiting Praxis Precision Medicines' forecast page.

What is Praxis Precision Medicines's operating income?

Praxis Precision Medicines's total operating income in 2024 was -$200.17 million, based on the following breakdown:

Total Gross Profit: $8.55 million
Total Operating Expenses: $208.72 million

How has Praxis Precision Medicines revenue changed over the last 2 years?

Over the last 2 years, Praxis Precision Medicines' total revenue changed from $0.00 in 2022 to $8.55 million in 2024, a change of 855,300,000.0%.

How much debt does Praxis Precision Medicines have?

Praxis Precision Medicines' total liabilities were at $37.66 million at the end of 2024, a 106.0% increase from 2023, and a 3.5% decrease since 2022.

How much cash does Praxis Precision Medicines have?

In the past 2 years, Praxis Precision Medicines' cash and equivalents has ranged from $61.62 million in 2022 to $215.37 million in 2024, and is currently $215.37 million as of their latest financial filing in 2024.

How has Praxis Precision Medicines' book value per share changed over the last 2 years?

Over the last 2 years, Praxis Precision Medicines' book value per share changed from 1.62 in 2022 to 23.90 in 2024, a change of 1,379.7%.

Related Companies

This page (NASDAQ:PRAX) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Praxis Precision Medicines (PRAX) Financials

Frequently Asked Questions About Praxis Precision Medicines' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Praxis Precision Medicines (PRAX) Financials

Annual Income Statements for Praxis Precision Medicines

Quarterly Income Statements for Praxis Precision Medicines

Annual Cash Flow Statements for Praxis Precision Medicines

Quarterly Cash Flow Statements for Praxis Precision Medicines

Annual Balance Sheets for Praxis Precision Medicines

Quarterly Balance Sheets for Praxis Precision Medicines

Annual Metrics And Ratios for Praxis Precision Medicines

Quarterly Metrics And Ratios for Praxis Precision Medicines

Frequently Asked Questions About Praxis Precision Medicines' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools